Loading…

G149(P) Stroke-Recurrence in Nigerian Children with Sickle Cell Anaemia Treated with Hydroxyurea After a First Clinical Stroke

Background Chronic blood transfusion is the standard treatment for secondary stroke prevention in sickle cell anaemia (SCA) but this treatment option poses major challenges in resource-poor countries of the world, especially malaria-endemic ones. Objective To compare the outcomes after a first clini...

Full description

Saved in:
Bibliographic Details
Published in:Archives of disease in childhood 2013-06, Vol.98 (Suppl 1), p.A69-A69
Main Authors: Lagunju, IA, Brown, BJ, Sodeinde, O
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page A69
container_issue Suppl 1
container_start_page A69
container_title Archives of disease in childhood
container_volume 98
creator Lagunju, IA
Brown, BJ
Sodeinde, O
description Background Chronic blood transfusion is the standard treatment for secondary stroke prevention in sickle cell anaemia (SCA) but this treatment option poses major challenges in resource-poor countries of the world, especially malaria-endemic ones. Objective To compare the outcomes after a first clinical stroke, with and without treatment with hydroxyurea (HU). Methods Over a 6-year period, Nigerian children with SCA who had suffered a first stroke was studied. Outcomes in those who received HU (25mg/kg/day) were compared with those whose parents declined both HU and chronic transfusion. Results Thirty-two children, all with haemoglobin SS phenotype (SCA) presented with stroke and one died of haemorrhagic stroke at presentation. Age at first clinical stroke (Mean +/- SD) was 7.58 (+/-2.33) years. Thirteen children received HU while 18 declined HU therapy. The secondary stroke incidence of 7/100 person years in the HU group was significantly lower than the 28/100 person years in the non-HU group (P = 0.001, OR 3.808, 95% CI 1.556, 9.317). Children who did not receive HU were more likely to drop out of school and to have moderate-severe motor disabilities requiring caregiver assistance for activities of daily living. Conclusion In settings where facilities for chronic blood transfusion are not accessible or feasible, HU therapy should be considered for secondary stroke prevention in children with SCA. Since, as far as we are aware, this is the first use of HU in a malaria-endemic setting, the possible impact of HU on drug-resistance in malaria needs to be carefully studied. Reference Lagunju I, Sodeinde O, Telfer P. Prevalence of transcranial Doppler abnormalities in Nigerian children with sickle cell disease. Am J Hematol. 2012 May; 87(5):544–7. doi: 10.1002/ajh.23152. Epub 2012 Mar 28. PubMed PMID: 22460323. Abstract G149(P) Table 1 Comparison of the demographics, clinical features and outcomes in the HU and non-HU groups HU group (N = 13) Non-HU group (N = 18) P-value Mean follow-up time after first stroke in years (SD) 2.6 (1.2) 2.5 (1.1) 0.896 Stroke recurrence 7 28 0.001 Incidence of stroke recurrence/100 15.4 77.8 0.001 person-years 145 140 0.175 Stroke recurrence (%) Mean time to stroke-recurrence (months) Outcome at end of follow up period N (%) N (%)
doi_str_mv 10.1136/archdischild-2013-304107.161
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1727697138</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4214856611</sourcerecordid><originalsourceid>FETCH-LOGICAL-b2541-186a17e253bf87d39e6b0bbae6c177ecc094adba926f8d13ca97be7ed093b5473</originalsourceid><addsrcrecordid>eNqVkUFv1DAQhSMEEkvhP1iCQzmkeGIntiUuS2C3SKWgtnC1bGfCejebFDsR3Vsv_FF-CV4FIcSN00hP35s3mpdlL4CeAbDqlQlu0_joNr5r8oICyxnlQMUZVPAgWwCvZJI5f5gtKKUsV1LKx9mTGLeUQiElW2T3a-Dq9NPLn_c_rscw7DC_QjeFgL1D4nty6b9i8KYn9TEkyeS7Hzfk2rtdh6TGriPL3uDeG3IT0IzYzMD5oQnD3WFKGlm2IwZiyMqHOJK68713piNz3tPsUWu6iM9-z5Ps8-rdTX2eX3xcv6-XF7ktSg45yMqAwKJktpWiYQorS601WDkQAp2jipvGGlVUrWyAOaOERYENVcyWXLCT7HTeexuGbxPGUe_T59L9psdhihpEISolgMmEPv8H3Q5T6NN1GmR6myxKUSbq9Uy5MMQYsNW3we9NOGig-liP_rsefaxHz_XoVE-y57PdxxHv_nhN2OlKMFHqyy-1fgv8ar368EarxIuZt_vt_yX9Aub0qQQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1828882575</pqid></control><display><type>article</type><title>G149(P) Stroke-Recurrence in Nigerian Children with Sickle Cell Anaemia Treated with Hydroxyurea After a First Clinical Stroke</title><source>Social Science Premium Collection</source><source>Education Collection</source><creator>Lagunju, IA ; Brown, BJ ; Sodeinde, O</creator><creatorcontrib>Lagunju, IA ; Brown, BJ ; Sodeinde, O</creatorcontrib><description>Background Chronic blood transfusion is the standard treatment for secondary stroke prevention in sickle cell anaemia (SCA) but this treatment option poses major challenges in resource-poor countries of the world, especially malaria-endemic ones. Objective To compare the outcomes after a first clinical stroke, with and without treatment with hydroxyurea (HU). Methods Over a 6-year period, Nigerian children with SCA who had suffered a first stroke was studied. Outcomes in those who received HU (25mg/kg/day) were compared with those whose parents declined both HU and chronic transfusion. Results Thirty-two children, all with haemoglobin SS phenotype (SCA) presented with stroke and one died of haemorrhagic stroke at presentation. Age at first clinical stroke (Mean +/- SD) was 7.58 (+/-2.33) years. Thirteen children received HU while 18 declined HU therapy. The secondary stroke incidence of 7/100 person years in the HU group was significantly lower than the 28/100 person years in the non-HU group (P = 0.001, OR 3.808, 95% CI 1.556, 9.317). Children who did not receive HU were more likely to drop out of school and to have moderate-severe motor disabilities requiring caregiver assistance for activities of daily living. Conclusion In settings where facilities for chronic blood transfusion are not accessible or feasible, HU therapy should be considered for secondary stroke prevention in children with SCA. Since, as far as we are aware, this is the first use of HU in a malaria-endemic setting, the possible impact of HU on drug-resistance in malaria needs to be carefully studied. Reference Lagunju I, Sodeinde O, Telfer P. Prevalence of transcranial Doppler abnormalities in Nigerian children with sickle cell disease. Am J Hematol. 2012 May; 87(5):544–7. doi: 10.1002/ajh.23152. Epub 2012 Mar 28. PubMed PMID: 22460323. Abstract G149(P) Table 1 Comparison of the demographics, clinical features and outcomes in the HU and non-HU groups HU group (N = 13) Non-HU group (N = 18) P-value Mean follow-up time after first stroke in years (SD) 2.6 (1.2) 2.5 (1.1) 0.896 Stroke recurrence 7 28 0.001 Incidence of stroke recurrence/100 15.4 77.8 0.001 person-years 145 140 0.175 Stroke recurrence (%) Mean time to stroke-recurrence (months) Outcome at end of follow up period N (%) N (%) &lt;0.001 Moderate-Severe motor disability 3 (23.1) 16 (88.9) 0.003 Drop-out from school 1 (7.7) 11 (61.1) 0.499 Epilepsy 3 (23.1) 3 (16.7) 0.606 Learning diffi culties 7 (53.8) 10 (55.6)</description><identifier>ISSN: 0003-9888</identifier><identifier>EISSN: 1468-2044</identifier><identifier>DOI: 10.1136/archdischild-2013-304107.161</identifier><identifier>CODEN: ADCHAK</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</publisher><subject>Malaria ; Prevention ; Transfusion ; Vector-borne diseases</subject><ispartof>Archives of disease in childhood, 2013-06, Vol.98 (Suppl 1), p.A69-A69</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1828882575/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1828882575?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,21378,21394,27924,27925,33611,33612,33877,33878,43733,43880,74221,74397</link.rule.ids></links><search><creatorcontrib>Lagunju, IA</creatorcontrib><creatorcontrib>Brown, BJ</creatorcontrib><creatorcontrib>Sodeinde, O</creatorcontrib><title>G149(P) Stroke-Recurrence in Nigerian Children with Sickle Cell Anaemia Treated with Hydroxyurea After a First Clinical Stroke</title><title>Archives of disease in childhood</title><addtitle>Arch Dis Child</addtitle><description>Background Chronic blood transfusion is the standard treatment for secondary stroke prevention in sickle cell anaemia (SCA) but this treatment option poses major challenges in resource-poor countries of the world, especially malaria-endemic ones. Objective To compare the outcomes after a first clinical stroke, with and without treatment with hydroxyurea (HU). Methods Over a 6-year period, Nigerian children with SCA who had suffered a first stroke was studied. Outcomes in those who received HU (25mg/kg/day) were compared with those whose parents declined both HU and chronic transfusion. Results Thirty-two children, all with haemoglobin SS phenotype (SCA) presented with stroke and one died of haemorrhagic stroke at presentation. Age at first clinical stroke (Mean +/- SD) was 7.58 (+/-2.33) years. Thirteen children received HU while 18 declined HU therapy. The secondary stroke incidence of 7/100 person years in the HU group was significantly lower than the 28/100 person years in the non-HU group (P = 0.001, OR 3.808, 95% CI 1.556, 9.317). Children who did not receive HU were more likely to drop out of school and to have moderate-severe motor disabilities requiring caregiver assistance for activities of daily living. Conclusion In settings where facilities for chronic blood transfusion are not accessible or feasible, HU therapy should be considered for secondary stroke prevention in children with SCA. Since, as far as we are aware, this is the first use of HU in a malaria-endemic setting, the possible impact of HU on drug-resistance in malaria needs to be carefully studied. Reference Lagunju I, Sodeinde O, Telfer P. Prevalence of transcranial Doppler abnormalities in Nigerian children with sickle cell disease. Am J Hematol. 2012 May; 87(5):544–7. doi: 10.1002/ajh.23152. Epub 2012 Mar 28. PubMed PMID: 22460323. Abstract G149(P) Table 1 Comparison of the demographics, clinical features and outcomes in the HU and non-HU groups HU group (N = 13) Non-HU group (N = 18) P-value Mean follow-up time after first stroke in years (SD) 2.6 (1.2) 2.5 (1.1) 0.896 Stroke recurrence 7 28 0.001 Incidence of stroke recurrence/100 15.4 77.8 0.001 person-years 145 140 0.175 Stroke recurrence (%) Mean time to stroke-recurrence (months) Outcome at end of follow up period N (%) N (%) &lt;0.001 Moderate-Severe motor disability 3 (23.1) 16 (88.9) 0.003 Drop-out from school 1 (7.7) 11 (61.1) 0.499 Epilepsy 3 (23.1) 3 (16.7) 0.606 Learning diffi culties 7 (53.8) 10 (55.6)</description><subject>Malaria</subject><subject>Prevention</subject><subject>Transfusion</subject><subject>Vector-borne diseases</subject><issn>0003-9888</issn><issn>1468-2044</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>ALSLI</sourceid><sourceid>CJNVE</sourceid><sourceid>M0P</sourceid><recordid>eNqVkUFv1DAQhSMEEkvhP1iCQzmkeGIntiUuS2C3SKWgtnC1bGfCejebFDsR3Vsv_FF-CV4FIcSN00hP35s3mpdlL4CeAbDqlQlu0_joNr5r8oICyxnlQMUZVPAgWwCvZJI5f5gtKKUsV1LKx9mTGLeUQiElW2T3a-Dq9NPLn_c_rscw7DC_QjeFgL1D4nty6b9i8KYn9TEkyeS7Hzfk2rtdh6TGriPL3uDeG3IT0IzYzMD5oQnD3WFKGlm2IwZiyMqHOJK68713piNz3tPsUWu6iM9-z5Ps8-rdTX2eX3xcv6-XF7ktSg45yMqAwKJktpWiYQorS601WDkQAp2jipvGGlVUrWyAOaOERYENVcyWXLCT7HTeexuGbxPGUe_T59L9psdhihpEISolgMmEPv8H3Q5T6NN1GmR6myxKUSbq9Uy5MMQYsNW3we9NOGig-liP_rsefaxHz_XoVE-y57PdxxHv_nhN2OlKMFHqyy-1fgv8ar368EarxIuZt_vt_yX9Aub0qQQ</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Lagunju, IA</creator><creator>Brown, BJ</creator><creator>Sodeinde, O</creator><general>BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88B</scope><scope>88E</scope><scope>88I</scope><scope>8A4</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>CJNVE</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0P</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEDU</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>C1K</scope><scope>F1W</scope><scope>H95</scope><scope>H97</scope><scope>L.G</scope></search><sort><creationdate>201306</creationdate><title>G149(P) Stroke-Recurrence in Nigerian Children with Sickle Cell Anaemia Treated with Hydroxyurea After a First Clinical Stroke</title><author>Lagunju, IA ; Brown, BJ ; Sodeinde, O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b2541-186a17e253bf87d39e6b0bbae6c177ecc094adba926f8d13ca97be7ed093b5473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Malaria</topic><topic>Prevention</topic><topic>Transfusion</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lagunju, IA</creatorcontrib><creatorcontrib>Brown, BJ</creatorcontrib><creatorcontrib>Sodeinde, O</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Education Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Education Periodicals</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Education Collection</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Education Database</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Education</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 1: Biological Sciences &amp; Living Resources</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 3: Aquatic Pollution &amp; Environmental Quality</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) Professional</collection><jtitle>Archives of disease in childhood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lagunju, IA</au><au>Brown, BJ</au><au>Sodeinde, O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>G149(P) Stroke-Recurrence in Nigerian Children with Sickle Cell Anaemia Treated with Hydroxyurea After a First Clinical Stroke</atitle><jtitle>Archives of disease in childhood</jtitle><addtitle>Arch Dis Child</addtitle><date>2013-06</date><risdate>2013</risdate><volume>98</volume><issue>Suppl 1</issue><spage>A69</spage><epage>A69</epage><pages>A69-A69</pages><issn>0003-9888</issn><eissn>1468-2044</eissn><coden>ADCHAK</coden><abstract>Background Chronic blood transfusion is the standard treatment for secondary stroke prevention in sickle cell anaemia (SCA) but this treatment option poses major challenges in resource-poor countries of the world, especially malaria-endemic ones. Objective To compare the outcomes after a first clinical stroke, with and without treatment with hydroxyurea (HU). Methods Over a 6-year period, Nigerian children with SCA who had suffered a first stroke was studied. Outcomes in those who received HU (25mg/kg/day) were compared with those whose parents declined both HU and chronic transfusion. Results Thirty-two children, all with haemoglobin SS phenotype (SCA) presented with stroke and one died of haemorrhagic stroke at presentation. Age at first clinical stroke (Mean +/- SD) was 7.58 (+/-2.33) years. Thirteen children received HU while 18 declined HU therapy. The secondary stroke incidence of 7/100 person years in the HU group was significantly lower than the 28/100 person years in the non-HU group (P = 0.001, OR 3.808, 95% CI 1.556, 9.317). Children who did not receive HU were more likely to drop out of school and to have moderate-severe motor disabilities requiring caregiver assistance for activities of daily living. Conclusion In settings where facilities for chronic blood transfusion are not accessible or feasible, HU therapy should be considered for secondary stroke prevention in children with SCA. Since, as far as we are aware, this is the first use of HU in a malaria-endemic setting, the possible impact of HU on drug-resistance in malaria needs to be carefully studied. Reference Lagunju I, Sodeinde O, Telfer P. Prevalence of transcranial Doppler abnormalities in Nigerian children with sickle cell disease. Am J Hematol. 2012 May; 87(5):544–7. doi: 10.1002/ajh.23152. Epub 2012 Mar 28. PubMed PMID: 22460323. Abstract G149(P) Table 1 Comparison of the demographics, clinical features and outcomes in the HU and non-HU groups HU group (N = 13) Non-HU group (N = 18) P-value Mean follow-up time after first stroke in years (SD) 2.6 (1.2) 2.5 (1.1) 0.896 Stroke recurrence 7 28 0.001 Incidence of stroke recurrence/100 15.4 77.8 0.001 person-years 145 140 0.175 Stroke recurrence (%) Mean time to stroke-recurrence (months) Outcome at end of follow up period N (%) N (%) &lt;0.001 Moderate-Severe motor disability 3 (23.1) 16 (88.9) 0.003 Drop-out from school 1 (7.7) 11 (61.1) 0.499 Epilepsy 3 (23.1) 3 (16.7) 0.606 Learning diffi culties 7 (53.8) 10 (55.6)</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</pub><doi>10.1136/archdischild-2013-304107.161</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0003-9888
ispartof Archives of disease in childhood, 2013-06, Vol.98 (Suppl 1), p.A69-A69
issn 0003-9888
1468-2044
language eng
recordid cdi_proquest_miscellaneous_1727697138
source Social Science Premium Collection; Education Collection
subjects Malaria
Prevention
Transfusion
Vector-borne diseases
title G149(P) Stroke-Recurrence in Nigerian Children with Sickle Cell Anaemia Treated with Hydroxyurea After a First Clinical Stroke
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T18%3A55%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=G149(P)%E2%80%85Stroke-Recurrence%20in%20Nigerian%20Children%20with%20Sickle%20Cell%20Anaemia%20Treated%20with%20Hydroxyurea%20After%20a%20First%20Clinical%20Stroke&rft.jtitle=Archives%20of%20disease%20in%20childhood&rft.au=Lagunju,%20IA&rft.date=2013-06&rft.volume=98&rft.issue=Suppl%201&rft.spage=A69&rft.epage=A69&rft.pages=A69-A69&rft.issn=0003-9888&rft.eissn=1468-2044&rft.coden=ADCHAK&rft_id=info:doi/10.1136/archdischild-2013-304107.161&rft_dat=%3Cproquest_cross%3E4214856611%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b2541-186a17e253bf87d39e6b0bbae6c177ecc094adba926f8d13ca97be7ed093b5473%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1828882575&rft_id=info:pmid/&rfr_iscdi=true